Gilead Sciences, Inc. (NASDAQ:GILD)

CAPS Rating: 4 out of 5

A biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.

Recs

1
Player Avatar TMFTailwind (50.05) Submitted: 5/30/2013 11:58:12 AM : Outperform Start Price: $56.18 GILD Score: +38.14

Very profitable company, and I expect GILD's streak of profitability to continue to increase. No significant patent expiration until 2018. With the current success in the HIV market, if the company can find success in a new category via R&D efforts, this could turn out to be a big winner.

Featured Broker Partners


Advertisement